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Purpose: The aims of this article were to system-
atically review the literature about the mechanism of
action of colchicine in the multimodal pathology of
acute inﬂammation associated with gout and to
consider the clinical utility of colchicine in other
chronic inﬂammatory diseases.
Methods: The English-language literature on
PubMed was searched for articles published between
1990 and October 2013, with a cross-reference to
citations across all years. Relevant articles pertaining
to the mechanism of action of colchicine and the
clinical applications of colchicine in gout and other
inﬂammatory conditions were identiﬁed and reviewed.
Findings: The molecular pathology of acute inﬂam-
mation associated with gouty arthritis involves several
concurrent pathways triggered by a variety of inter-
actions between monosodium urate crystals and the
surface of cells. Colchicine modulates multiple pro-
and antiinﬂammatory pathways associated with gouty
arthritis. Colchicine prevents microtubule assembly
and thereby disrupts inﬂammasome activation,
microtubule-based inﬂammatory cell chemotaxis, gen-
eration of leukotrienes and cytokines, and phagocy-
tosis. Many of these cellular processes can be found in
other diseases involving chronic inﬂammation. The
multimodal mechanism of action of colchicine sug-
gests potential efﬁcacy of colchicine in other comorbid
conditions associated with gout, such as osteoarthritis
and cardiovascular disease.
Implications: Colchicine has multiple mechanisms
of action that affect inﬂammatory processes and result
in its utility for treating and preventing acute gout
ﬂare. Other chronic inﬂammatory diseases that
invoke these molecular pathways may represent new
therapeutic applications for colchicine. (Clin Ther.
2014;36:1465–1479) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: colchicine, gout, inﬂammatory arthritis,
mechanism of action.October 2014INTRODUCTION
Gout is an inﬂammatory arthritis that is the result of
the precipitation of serum urate into crystallized
deposits of monosodium urate (MSU) in and around
the joint. These crystals cause recurrent episodes of
severe inﬂammatory arthritis that present as swelling,
redness, heat, pain, and stiffness in the joints, most
often seen in the ﬁrst metatarsophalangeal joint.
Colchicine is a natural product originally extracted
from plants of the genus Colchicum (autumn crocus)
and has been used to treat gouty arthritis for centu-
ries.1 Clinical trial results have demonstrated that low-
dose colchicine is effective for the management of
acute gout ﬂares as well as for long-term prophylactic
maintenance.2–4
Current treatment guidelines recognize the efﬁcacy
of colchicine in the treatment of acute gouty arthritis
and for the prevention of gout ﬂares. The American
College of Rheumatology Guidelines for Management
of Gout recommend the pharmacologic treatment of
acute gout ﬂares within 24 hours of onset and
recommend colchicine, NSAIDs, selective cyclo-
oxygenase-2 inhibitors, and corticosteroids as ﬁrst-
line therapies for treating the pain of acute ﬂares.5
A recent update of the European League Against
Rheumatism (EULAR) guidelines for the manage-
ment of gout, carried out by a multidisciplinary
panel of experts from the United States, also
recommends that the initial treatment of acute gout
ﬂares begin with low-dose colchicine, NSAIDs, and
glucocorticoids.6 The EULAR guidelines indicate that
prophylaxis for acute gout attacks during the ﬁrst 6 to
12 months of therapy with urate-lowering agents can
be achieved with colchicine.61465
Clinical TherapeuticsThese changes in treatment guidance have been the
result of an increased understanding of the molecular
pathology underlying the acute inﬂammation associ-
ated with gout and the potential beneﬁts of early and
aggressive treatment. In light of this new information,
there is growing evidence that the therapeutic response
of colchicine is multifaceted and intervenes at several
different pathways involved in inﬂammation. The
objectives of this review were to determine the current
views regarding the mechanism of action of colchicine
and to consider the potential clinical utility of colchi-
cine in other chronic inﬂammatory diseases.
MATERIALS AND METHODS
The PubMed database was searched for relevant studies
published between 1990 and October 2013 and re-
stricted to the English language. All medical-subject
heading searches were explored using Boolean-based
key word search criteria and included the terms gout,
inﬂammation, colchicine, osteoarthritis, and cardiovas-
cular disease. The focus was on the following questions:
(1) What is the process of inﬂammation in gout?; (2)
What is the mechanism of action of colchicine?; and (3)
What are the clinical applications of colchicine in gout
and other medical conditions? Additionally, references
noted in relevant articles were also accessed and re-
viewed. Studies that included original research and
explored recent advances in the understanding of the
molecular pathology of inﬂammation associated with
gout, the multimodal mechanism of action of colchicine
in response to inﬂammation, and the potential use of
colchicine in other chronic inﬂammatory diseases were
critically discussed.
RESULTS
A total of 756 scientiﬁc and clinical articles published
in English were identiﬁed through a cross-comparative
search. After medical review, 693 were evaluated as
outside the scope of the focus of this review. The
remaining 63 publications were carefully reviewed to
identify potentially relevant articles for retrieval.
Inflammation and Gout
Awareness of the multiple actions of colchicine in
gout requires an understanding of the inﬂammatory
cascade underlying the symptoms of this debilitating
disease. Gout is a disease process triggered by inter-
actions between MSU microcrystals and the local
tissue environment. The affected synovium of patients1466with acute gouty arthritis is inﬁltrated with neutro-
phils, mononuclear phagocytes, and lymphocytes,
resulting in marked swelling of the tissues and vas-
cular injury.7 The biochemical mechanisms that link
MSU crystal precipitation with joint inﬂammation
have not been deﬁnitively elucidated and likely in-
volve a variety of leukocytes, cytokines, and chemo-
kines that participate in the innate immune system
response (Figure).MSU Crystal Formation
Precipitation of urate into MSU crystals is central
in acute gouty arthritis. However, the mechanism by
which MSU crystals form directly at the site of joint
inﬂammation is not well understood. Monosodium
urate crystallizes when the plasma concentration of
urate exceeds its solubility (7 mg/dL).9 Factors in
addition to plasma concentration that have been
shown to affect urate solubility in vitro include pH,
temperature, ionic strength, and the binding of urate
to plasma macromolecules.9–13 However, environ-
mental conditions and/or mechanisms favoring/limit-
ing crystal formation in vivo are likely different from
in vitro models. The de novo formation of MSU
crystals within the joint may be triggered by excessive
alcohol or red meat intake and large-scale cell death
from trauma, surgery, or anticancer therapies. Plasma
macromolecules such as albumin have been suggested
as possible MSU crystal–nucleating agents.11,14 Cir-
culating antibodies, including immunoglobulin (Ig) G
and IgM, recognize MSU crystal surfaces, stabilize
them, and promote further crystallization.15–17MSU Crystal Stimulation of Pro-Inflammatory Cells
Endogenous MSU crystals act as danger-associated
molecular patterns (DAMPs) that are recognized by
the innate immune system, notably neutrophils and
macrophages/monocytes, as well as mast cells and
dendritic cells.8,18–21 Uric acid DAMP signaling acti-
vates dendritic cells and macrophages to secrete pro-
inﬂammatory cytokines, including interleukin (IL)-
1β.22,23 The mechanism by which pro-inﬂammatory
cells interact with MSU crystals is a major area of
research focus and likely involves different pathways
operating simultaneously to initiate the inﬂammatory
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Figure. Mechanisms of monosodium urate (MSU) crystal–mediated inflammation in acute gouty arthritis. (1)
MSU crystals interact with the surface of dendritic cells through crystal-lipid contact in a manner that
does not rely on specific cell surface receptors. Lipid bilayer perturbation may trigger an intracellular
signaling cascade, leading to spleen tyrosine kinase (Syk) activation and additional dendritic cell
activation.8 (2) MSU crystals bind to Toll-like receptors (TLRs). In the presence of myeloid
differentiation factor 88 (MyD88), nuclear factor (NF)-κB is induced and pro-inflammatory
molecules are released. The expression of multiple adhesion molecules on the surface of
endothelial cells is increased. (3) MSU crystal phagocytosis leads to phagolysosomal damage,
which leads to potassium efflux. The addition of available reactive oxygen species (ROS), ASC, and
pro-caspase-1 to the nucleotide-binding domain, leucine-rich repeat-containing 3 (NLR3) receptor
forms the NLRP3 inflammasome complex, which induces interleukin (IL)-1β. ASC, apoptosis-
associated speck-like protein containing a caspase recruitment domain; TNF, tumor necrosis factor.
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The nucleotide-binding domain, leucine-rich re-
peat-containing (NLR) family of receptors plays an
important role in the recognition of danger-associated
signals. Together with the adaptor apoptosis-
associated speck-like protein containing a caspase
recruitment domain (ASC) and pro–caspase-1, NLRs
form a multiprotein complex—the inﬂammasome—
which induces pro-inﬂammatory cytokines, most no-
tably IL-1β.24 Expressed in myeloid cells, theOctober 2014inﬂammasome is a multiprotein oligomer that
consists of caspase-1, caspase-5, NLRP, and
PYCARD. The inﬂammasome is a component of the
innate immune system and has been shown to be
involved in the activation of many inﬂammatory
processes.25 In 2006, Martinon et al26 reported that
the NLRP3 (formerly NALP3) inﬂammasome is
speciﬁcally activated by MSU crystals.
The steps that link cellular contact of MSU crystals
with activation of the NLRP3 inﬂammasome involve1467
Clinical Therapeuticsphagocytosis of crystals, potassium efﬂux, and the
generation of reactive oxygen species.27–31On activa-
tion, the NLRP3 inﬂammasome recruits and activates
caspase-1, which then goes on to produce mature IL-
1β from the pro-IL-1β precursor.32,33 Recent work has
implicated the action of microtubules as being central
in the assembly and activation of the inﬂammasome.34
Macrophages and Monocytes
Both resident macrophages and MSU-recruited
monocytes that differentiate into macrophages contrib-
ute to gout-associated inﬂammation.35 Toll-like recep-
tors (TLRs)-2 and -4 and the cytosolic TLR adapter
protein myeloid differentiation factor 88 (MyD88)
contribute to the activation of macrophages by MSU
crystals.36,37 Once stimulated, TLRs and the IL-1β
receptor associate with a number of intracellular
adaptor molecules, including MyD88, to trigger a
signaling cascade that activates pro-inﬂammatory tran-
scription factors, such as nuclear factor (NF)-κB, and
increases release of pro-inﬂammatory molecules such as
tumor necrosis factor (TNF)-α, IL-6, and IL-8.18,22,38–40
Results from ex vivo experiments showed that stim-
ulation of resident peritoneal macrophages with MSU
crystals increased expression of multiple inﬂammatory
cytokines, including IL-1β, IL-6, and TNF-α. Additional
in vivo studies showed that depletion of resident
macrophages resulted in decreased cytokine produc-
tion.20 Additionally, monocytes recruited to sites of
MSU crystal deposition differentiate into pro-
inﬂammatory M1-like macrophages.35 It has been
suggested that stimulation of these macrophages by
fresh MSU crystals results in a secondary wave of
inﬂammation in acute gout ﬂares.35
Neutrophils
Secretion of TNF-α, IL-1β, IL-6, and IL-8 by
monocytes that have been stimulated with MSU
crystals increases expression of multiple adhesion
molecules on the surface of endothelial cells, including
E-selectin, intercellular adhesion molecule-1, and vas-
cular cell adhesion molecule-1. This, in turn, leads to
recruitment of neutrophils to sites of crystal deposi-
tion.19 Neutrophils have been shown to contribute to
IL-1β production in some inﬂammatory states, which
may also be the case in MSU crystal–induced inﬂam-
mation.41 MSU crystals rapidly stimulate tyrosine
phosphorylation in neutrophils, leading to the
production of superoxide anions necessary for1468NLRP3 assembly and neutrophil activation.42,43 Acti-
vation of neutrophils in gout is associated with the
formation of pro-inﬂammatory neutrophil extracellu-
lar traps, which are associated with both autophagy
and IL-1β production.44 Prolonged exposure to
neutrophil extracellular traps increases the risk for
chronic inﬂammation; the synovial ﬂuid and joint
tissue of patients with gout also reveal neutrophil
extracellular trap formation, particularly during
ﬂares.45
Dendritic Cells
Dendritic cells are antigen-presenting cells that
detect DAMPs and propagate signaling cascades,
leading to nuclear translocation of transcription fac-
tors and escalation of inﬂammation. MSU crystals
interact with the surface of dendritic cells through
crystal–lipid contact in a manner that does not rely on
speciﬁc cell-surface receptors.8 MSU crystals engage
the lipid surface of dendritic cells, thereby perturbing
the lipid bilayer and causing lipid and cholesterol
shifting. Ng et al8 proposed that this lipid sorting
initiates an intracellular signaling cascade that triggers
spleen tyrosine kinase and leads to subsequent
dendritic cell activation.
Mast Cells
Mast cells are involved in the early phase response
to MSU crystal–induced inﬂammation based on re-
sults from the rat peritonitis model.8 On introduction
of MSU crystals to the peritoneal cavity, mast cell
inﬁltrates were identiﬁed in the subintimal layer of the
peritoneal membrane before monocyte/macrophage
and neutrophil inﬂux to the membrane.21 On acti-
vation, mast cells release factors such as TNF-α, IL-1β,
platelet-activating factor, and histamine to regulate
endothelial cell adhesion molecules and promote
inﬂammatory ampliﬁcation.46,47
Complement
MSU crystal–induced activation of both the classic
and the alternative complement pathways contributes
to acute gouty inﬂammation.48 Complement compo-
nents including C1q, C1r, and C1s, as well as IgG and
IgM, bind to MSU crystals, and the activation process
is ampliﬁed by the presence of these proteins.49 MSU-
mediated activation of the classic pathway will also
occur in the absence of Ig, indicating that MSU
crystals can directly initiate the classic cascade.50Volume 36 Number 10
N. Dalbeth et al.Activation of the alternative pathway leads to the pro-
duction of C5a and C5b fragments by a C5 convertase
localized on the surface of MSU crystals. These frag-
ments act as potent leukocyte chemo-attractants.51
Additionally, in response to MSU crystals, the C6-
mediated formation of the membrane attack complex
has a substantial role in IL-8 production and subse-
quent neutrophil inﬂux in acute gouty inﬂammation.52
Hypernociception
Severe joint pain is the central experience of individ-
uals with acute gouty arthritis. Neutrophils and asso-
ciated pro-inﬂammatory cytokines, including TNF-α, IL-
1β, and IL-8, play a crucial role in inﬂammatory
hypernociception.53,54 Amaral et al41 injected MSU crys-
tals into the joints of mice to stimulate an inﬂammatory
response in the synovial ﬂuid and surrounding tissue
and evaluated concomitant articular hypernociception.
Results demonstrated that hypernociceptive responses
were dependent on the activation of the NLRP3
inﬂammasome, IL-1β production, MyD88 activation,
and neutrophil accumulation. Caspase-1 has also been
shown to induce hypernociception by promoting IL-1β
secretion.54
Resolution of Gout Attacks
Many gout attacks resolve spontaneously over 1
week, even without therapeutic intervention. A variety
of processes may contribute to the self-limiting nature
of gouty attacks, and multiple factors may be utilized.
Coating of MSU crystals by interstitial ﬂuid proteins
(apolipoproteins B and E) may decrease their ability to
initiate inﬂammation.55,56 Differentiated macrophages
may also contribute to gout attack resolution by
phagocytosis of crystals without stimulating inﬂamma-
tory events.57 These interactions may help to explain
the presence of MSU crystals in synovial ﬂuid after an
acute gout attack is resolved and in the synovial ﬂuid of
asymptomatic gout patients.58–60
Stimulation of antiinﬂammatory pathways may also
play a role in gout-attack resolution. Peroxisome
proliferator-activated receptor-γ is activated in gout at-
tacks, and ligands for this receptor inhibit transcription
of the genes encoding TNF-α, IL-1, IL-6, cyclooxygenase-
2, inducible nitric oxide synthase, and matrix metal-
loproteinases.61,62 Peroxisome proliferator-activated re-
ceptor-γ ligands promote monocyte expression of the
scavenger receptor CD36, which is involved in the
phagocytosis of apoptotic cells. This may increase rapidOctober 2014phagocytosis of apoptotic neutrophils by macrophages
and reduce damage associated with exposure to toxins
released from dying cells.63
Transforming growth factor (TGF)-β1 is an impor-
tant cytokine mediator in the resolution of MSU-
induced inﬂammation.64 Phagocytosis of apoptotic
neutrophils by macrophages and live neutrophils
triggers TGF-β1 production and release. Increased
TGF-β1 production suppresses neutrophil inﬂamma-
tory response and moderates IL-1 production.65–67
IL-8 is the principle cytokine involved in neutrophil
migration. Scanu et al68 demonstrated that the level of
IL-8 in synovial ﬂuid remains elevated 4 to 7 days
after the initiation of gout ﬂare. Maintenance of IL-8
levels allow for continued recruitment of neutrophils
to inﬂamed joints, enabling phagocytosis of apoptotic
neutrophils and increased TGF-β1 production. Addi-
tionally, suppressors of cytokine signaling, including
cytokine-inducible SH2-containing protein and sup-
pressor of cytokine signaling 3, are upregulated. These
2 factors are involved in suppressing IL-1β and TNF-α
production and promoting TGF-β1 production, which
contribute to the resolution of acute gout attacks.69
Mechanism of Action of Colchicine in Gouty
Arthritis
Colchicine affects the molecular pathology under-
lying acute inﬂammation associated with gouty arthri-
tis in a multimodal manner (Table). In vitro, at
micromolar concentrations, colchicine inhibits MSU
crystal activation of the NLRP3 inﬂammasome, blocks
the release of IL-1β, and suppresses the expression of
genes involved in cell regulation.26,34,70,71 At nano-
molar concentrations, colchicine modulates adhesion
protein expression on endothelial cells, inhibits IL-1–
induced L-selectin expression, modulates cytokine
maturation and release, and diminishes neutrophil
chemotaxis to cytokines.72,76,77 Whereas plasma con-
centration after single dosing of 0.6-mg colchicine is
approximately 3 nmol/L. it has been shown to accu-
mulate in a saturable manner in neutrophils to 40 to
200 nmol/L, well above its Ki of 24 nmol/L for
microtubule polymerization.78,79 The correlation of
the inhibition of microtubule polymerization with the
effects on these aforementioned pathways supports the
inhibition of microtubule polymerization by colchicine
and its effects on downstream pathways as a primary
target in the mechanism of action of this molecule in
the treatment of gout.341469
Table. Multimodal effects of the inhibition of microtubule polymerization by colchicine.
Biological Effect of Colchicine Study
Inhibits activation of the NLRP3 inﬂammasome in response
to inﬂammatory microcrystals
Martinon et al (2006)26
Suppresses the expression of NF-κB Jackman et al (2009)70
Decreases the number of TNF-α receptors on the surface of
macrophages and endothelial cells
Ding et al (1990)71
Decreases L-selectin expression on neutrophils Cronstein et al (1995)72
Alters the distribution of E-selectin on the surface of endothelial cells Cronstein et al (1995)72
Inhibits superoxide anion production in response to MSU crystals Roberge et al (1996)43; Chia et al
(2008)73
Interrupts mast cell degranulation process Oka et al (2005)74
Increases the level of TGF-β1 Yagnik et al (2004)67; Sayarlioglu
et al (2006)75
MSU ¼ monosodium urate; NF ¼ nuclear factor; NLR ¼ nucleotide-binding domain ¼ leucine-rich repeat-containing;
TGF ¼ transforming growth factor; TNF ¼ tumor necrosis factor.
Clinical TherapeuticsTubulin Disruption
Colchicine binds to both α- and β-tubulin to create
a tubulin–colchicine complex that prevents the for-
mation of microtubules.80,81 The state of microtubule
polymerization can control numerous cellular func-
tions, including intracellular organelle and vesicle
transport; secretion of cytokines and chemokines;
and migration, division, and regulation of gene ex-
pression.82 These actions inﬂuence the cell activity
known to be involved in inﬂammatory pathways
central to the pathogenesis of gout. Processes that
require microtubule-mediated recruitment or cytosolic
components, such as mitochondria and proteins such
as MyD88, ASC, spleen tyrosine kinase and other
kinases, to modulate the generation of cytokines and
chemoattractants, are all susceptible to modulation by
colchicine treatment. Microtubule disruption by col-
chicine has been studied extensively and is a primary
mechanism by which colchicine intervenes in the
molecular processes underlying gout inﬂammation;
however, it is probably not the only site of colchicine
action.NLRP3 Inﬂammasome
Colchicine interrupts the process by which MSU
crystals activate the NLRP3 inﬂammasome, thereby
preventing the processing of pro–IL-1β and the release1470of IL-1β.26 Colchicine suppression of the active
NLRP3 inﬂammasome stems from disruption of the
microtubule-mediated transport of mitochondria
(where endogenous ASC is localized) to the endoplas-
mic reticulum (ER; where NLRP3 is localized). The
co-localization of NLRP3 and ASC is required for
assembly and activation of the inﬂammasome to
produce mature IL-1β.34
Inhibition of Superoxide Anion Production
Colchicine has also been demonstrated to have an
effect in suppressing MSU crystal–induced tyrosine
phosphorylation and superoxide anion production in
human neutrophils in vitro and in murine peritoneal
macrophages.42,83 The colchicine-mediated inhibition
of reactive oxygen species production necessary for
inﬂammasome activation has been shown to be caused by
the microtubule-disrupting effect of colchicine.42,43,73,83
The inhibition of MSU-induced superoxide produc-
tion by neutrophils can be accomplished in vivo at
doses 100-fold lower than those required to inhibit
neutrophil inﬁltration.73
Neutrophil–Endothelial Cell Interactions
Colchicine interferes with neutrophil adhesion and
recruitment to inﬂamed tissues by decreasing neutro-
phil L-selectin expression and changing the distributionVolume 36 Number 10
N. Dalbeth et al.of E-selectin on endothelial cells.72 By preventing the
formation of intact microtubule structures, colchicine
blocks trafﬁcking of E-selectin at the cell surface,
leading to changes in endothelial adhesiveness.72,76 At
nanomolar concentrations, colchicine is able to disrupt
the topography of E-selectin distribution on the surface
of endothelial cells, potentially providing a mechanism
for the prophylactic effect of colchicine on gout-related
inﬂammation.72 At micromolar concentrations, colchi-
cine decreases the expression of L-selectin on the
surface of neutrophils, thereby impairing the adhesion
between neutrophils and the endothelium. This obser-
vation provides a potential mechanism for the ther-
apeutic effect of colchicine on gout ﬂare.
Leukotriene B4 (LTB4) is a chemo-attractant and
mediator of inﬂammation that is required for MSU-
induced activation of the NLRP3 inﬂammasome and
subsequent release of IL-1β.41 LTB4 is also involved in
promoting the adhesion and mobility of neutrophils.84
Colchicine signiﬁcantly decreased LTB4-induced leu-
kocyte adherence and decreased LTB4-induced leu-
kocyte emigration from postcapillary venules.84 A
convergent downstream effect of LTB4 on inﬂammatory
cells is the microtubule-driven assembly and activation of
NLRP3, further supporting the microtubule as a primary
target for colchicine.34
TNF-α
Colchicine blunts TNF-α–induced activation of mac-
rophages and diminishes the number of TNF-α receptors
on the surface of macrophages and endothelial cells but
not on the surface of neutrophils. These ﬁndings were
attributed to colchicine-mediated destabilization of the
microtubule network.71 TNF-α–induced activation of
NF-κB is also inhibited by colchicine.70 Evidence from
Jackman et al70 suggested that microtubules are integral
to the regulation of the signaling cascade involved in
NF-κB activation. Colchicine-induced disruption of mi-
crotubules inhibits signal transduction of the TNF-α–
NF-κB pathway.
Mast Cells
Colchicine has been implicated in the interruption
of mast cell degranulation processes, thus preventing
the release of inﬂammatory mediators.74 This is believed
to be the result of colchicine-induced disruption of
microtubule-mediated granular transport. In addition,
with regard to allergen-mediated degranulation, micro-
tubules are involved in regulating calcium ion signalingOctober 2014between the ER and the plasma membrane, which is
necessary to initiate mast cell degranulation. In concert
with its effect on mitochondrial motility during the
assembly of NLRP3, colchicine was also shown to
disable proper ER arrangement within the cell to permit
calcium ion inﬂux, leading to attenuation of the allergic
response in vivo.34,74
Hypernociception
One pathway to hypernociception depends on
activation of the NLRP3 inﬂammasome, generation
of cytokines and leukotrienes, MyD88 recruitment,
and neutrophil chemotaxis.41 Interruption of these as
well as other processes may explain the ability of
colchicine to attenuate hypernociception. Additional
research indicates that colchicine-mediated microtu-
bule disruption affects sensory neurons attenuating
hyperalgesia independent of inﬂammation.85–87
Effects of Colchicine on Antiinflammatory Mediators
In addition to interfering with the actions of pro-
inﬂammatory pathways, colchicine also increases lev-
els of antiinﬂammatory molecules that may contribute
to clinical beneﬁt in patients with gout. TGF-β1 has
been shown to be elevated in the synovial ﬂuid of
patients with gout, and its levels are highest during the
resolution of gout attacks.68,88 Blood levels of this
potent antiinﬂammatory molecule are increased by
colchicine, and the decrease in IL-1β levels induced by
colchicine treatment may be expected to enhance
TGF-β1 signaling as described by Lim et al.75,89
Colchicine treatment has also been shown to provide
protection against oxidative stress and to increase the
activity of the antioxidant redox system in patients
with remission of familial Mediterranean fever
(FMF).90
More recent studies have investigated the mecha-
nism of action of colchicine in novel inﬂammatory
diseases, with a speciﬁc focus on the cytoskeleton. A
study by Taskiran et al91 investigated the effects
of colchicine on pyrin and its interacting proteins as
part of the potential pharmacologic effect in patients
with FMF. The investigators reported that colchicine
directly prevents the formation of reticulated ﬁbrils that
are generated by the cytosolic adaptor protein, proline-
serine-threonine phosphatase-interacting protein 1,
thereby preventing the transport of proline-, glutamic
acid–, serine-, and threonine-rich phosphatases to their
substrates. Colchicine also reduced ASC speck rates in1471
Clinical Therapeuticstransfected cells, as well as downregulated MEFV gene
expression and reorganization of actin cytoskeleton of
THP-1 cells. The investigators concluded that reorgan-
ization of the actin cytoskeleton may affect expression
of the MEFV gene and potentially explain the pharma-
cologic action of colchicine in FMF. Paschke et al77
investigated the effects of colchicine on the regulation
of cell motility, evaluating the reorganization of sub-
cellular compartments by which colchicine modulates
the elasticity, stiffness, and viscosity of neutrophils.
Colchicine, at therapeutic doses, was found to signif-
icantly affect the deformability and motility of human
neutrophils in conﬁned spaces, emphasizing the role of
the cytoskeleton as a pharmacologic target during any
inﬂammatory process in which activated neutrophils
are involved.
Colchicine Metabolism and Adverse Reactions
In the past, colchicine was administered both by the
oral and the intravenous routes. However, the latter
dosage formulation is no longer practiced due to serious
adverse events.92 The most common adverse reactions
reported with oral colchicine therapy in clinical trials in
gout were diarrhea (23%) and pharyngolaryngeal pain
(3%).2–4,93 These events were considered generally mild
and resolved with dose reduction. More severe adverse
events were observed with overdoses of colchicine,
including bone marrow suppression with agranulocyto-
sis. Colchicine is metabolized by the cytochrome P450
(CYP) 3A4 enzyme and it is also a substrate for the
P-glycoprotein 1 (P-gp) efﬂux transporter.94–96 Concur-
rent use of interacting drugs or the administration of
colchicine to patients with impaired renal function has
been associated with myopathy or rhabdomyolysis.97–99
For example, when P-gp or strong CYP3A4 inhibitors
(eg, cyclosporin, tacrolimus, ketoconazole, protease in-
hibitors, imidazole, and clarithromycin) are prescribed
in combination with colchicine, increased intracellular
accumulation of colchicine is likely and may lead to
adverse pharmacologic or toxic effects, such as muscle
weakness or pain, severe diarrhea or vomiting, abdomi-
nal pain, increased infections, or unusual bleeding or
bruising.95,100,101 Signiﬁcant adverse drug interactions
have occurred in patients treated with colchicine and
lipid-lowering drugs, such as simvastatin, that utilize the
CYP34A pathway of drug metabolism, causing muscle
aches, rhabdomyolysis, and/or myopathy.102–104 In ad-
dition, rhabdomyolysis was reported in a patient who
received colchicine with digoxin, a P-gp substrate.1051472Current prescribing information, based on drug–drug
interaction studies only recently conducted, recommend
dose reductions when colchicine is used in conjunction
with P-gp inhibitors or moderate/strong CYP3A4 inhib-
itors. Colchicine administration is contraindicated in
patients with renal or hepatic impairment receiving both
P-gp and strong CYP3A4 inhibitors concurrently.93
Both accidental and therapeutic poisoning deaths
have occurred with colchicine overdose.106 High
fatality rates have been reported after doses exceeding
0.5 mg/kg. Therapeutic overdose may occur at lower
doses, particularly in patients with renal impairment or
on P-gp or strong CYP3A4 inhibitors or in patients
given colchicine acutely with the high-dose “to-gastro-
intestinal-toxicity” approach. After colchicine overdose,
gastrointestinal symptoms occur within a day after acute
ingestion, followed by multiple organ failure 1 to 7 days
after ingestion. Myocardial toxicity may lead to acute
cardiovascular collapse and ventricular dysrhyth-
mias.107,108 Treatment options are very limited after
acute colchicine overdose. Early gastrointestinal decon-
tamination using gastric lavage and multidose activated
charcoal is recommended. Hemodialysis or hemoﬁltra-
tion is ineffective due to the large volume of distribution
of colchicine, and after decontamination, treatment is
mainly supportive.
Areas of Ongoing Clinical Interest
Colchicine affects many molecular targets and
disrupts multiple pathways involved in inﬂammation
associated with acute gout ﬂare. This role in the
regulation of inﬂammatory mediators suggests poten-
tial efﬁcacy of colchicine in other conditions involving
chronic inﬂammation, including other forms of arthri-
tis and cardiovascular disease.109–112
Colchicine in the Treatment of Other Forms of
Arthritis
Gout and osteoarthritis (OA) occur together in
many patients.113 The pathophysiology of OA is
characterized by upregulation of a large number of
cytokines, including IL-1β and TNF-α in the chon-
drocyte and resident macrophages of the affected
joints, which serve to initiate and accelerate disease
progression.114,115 These pro-inﬂammatory mediators
lead to the activation of destructive pathways involv-
ing extracellular matrix–degrading enzymes and bone
remodeling driven by the activation of NF-κB and
TGF-β.116,117 Several recent studies have indicatedVolume 36 Number 10
N. Dalbeth et al.that local elevations of IL-1β and TNF-α can modulate
the TGF-β pathway from a homeostatic to a patho-
genic role leading to OA, suggesting a potential role
for colchicine in the treatment of OA.118
A small-scale evaluation of colchicine in OA included
61 postmenopausal patients with primary knee OA who
were treated with colchicine 0.5 mg BID or placebo.
Results from this trial suggested that use of rescue
medication (acetaminophen) was signiﬁcantly lower in
the colchicine group compared with the placebo group
(Po 0.0001). Rates of improvement, as measured using
patients’ global assessment and physicians’ global assess-
ment, at the end of 3 months of follow-up were
signiﬁcant greater with colchicine compared with pla-
cebo (both, P o 0.0001).109 In another study, in 36
patients with knee OA, colchicine 0.5 mg BID or
placebo was added to nimesulide (an NSAID), and
patients were followed up for 5 months. A 30%
improvement rate, as measured by total Western
Ontario and McMaster Universities Osteoarthritis
Scale scores, at 20 weeks was noted in the group that
received colchicine (57.9%) versus the group treated
with placebo (23.5%) (P o 0.05). The percentage of
patients achieving a 30% reduction in index knee pain,
as measured by a visual analog scale, was signiﬁcantly
greater in the colchicine group compared with the
placebo group (52.6% vs 17.6%; P o 0.05).112 With
the known effect on the reduction of IL-1β in the
inﬂammatory state, future evaluation of colchicine
in patients with OA in the clinical setting seems
appropriate.
Calcium pyrophosphate (CPP) crystal deposition
disease (CPPD) has clinical similarities to gout and is
sometimes called pseudogout. Although the exact
mechanism of CPP crystallization is not clear, crystal
deposition depends on several factors including the
presence of extracellular proteins and the concentra-
tion of calcium ions, inorganic phosphate, and in-
organic pyrophosphate.119–121 Once CPP crystals
form, the release of IL-1β is triggered by CCP-
induced crystal activation of the NLRP3 inﬂamma-
some, and the inﬂammation cascade is initiated by
macrophages and mast cells.19,26,122
EULAR recently developed recommendations for
the management of CPPD and treating acute at-
tacks.123 Unlike in gout, there is no CPP-lowering
therapy available. For CPPD prophylaxis, the EULAR
recommendations include the use of colchicine (0.5–
1.0 mg/d) in combination with oral NSAIDs. As ofOctober 2014yet, there have been no registered clinical trials of
colchicine for the management of CPPD; however, in
many of the laboratory studies of colchicine and
neutrophil function, colchicine has been shown to
prevent neutrophil activation in response to micro-
crystal activation.83,123–125
Despite the central role of pro-inﬂammatory cyto-
kines such as TNF-α in other forms of inﬂammatory
arthritis, such as psoriatic arthritis, ankylosing spon-
dylitis, and rheumatoid arthritis, these forms of
inﬂammatory arthritis have proven resistant to colchi-
cine treatment.126,127 These observations suggest that
the pro-inﬂammatory pathways involved in the patho-
genesis and maintenance of inﬂammation in these
chronic rheumatic diseases are not molecular or
cellular targets for colchicine action.Cardiovascular Risk Reduction With Colchicine
Patients with gout typically have multiple comor-
bidities, notably hypertension, that increase the risk
for cardiovascular events.128 Gout itself may be an
independent risk factor for cardiac events and
mortality.129,130 Although colchicine has been shown
to act on cells and mediators of inﬂammation, there
are limited clinical data regarding its beneﬁt in
cardiovascular risk reduction. Results from a study
in patients with stable coronary artery disease and
elevated high-sensitivity C-reactive protein (CRP) (Z2
mg/L), a biomarker of inﬂammation, indicated that
the administration of colchicine 0.5 mg BID for 4
weeks resulted in a 60% relative decrease in high-
sensitivity CRP levels that was independent of aspirin
or statin use.131 In contrast, in a study in 80 patients
with acute coronary syndromes or acute ischemic
stroke, treatment with colchicine 1 mg/d for 1
month had no signiﬁcant effect on mean CRP
concentration or the percentage of patients achieving
CRP levels o2 mg/L. Treatment also had no
signiﬁcant effect on platelet function.132
NADPH oxidase mediates the production of super-
oxide anions by neutrophils. Superoxide anions cause
oxidative damage in chronic vascular diseases.133
Colchicine inhibits MSU-induced superoxide produc-
tion most likely through a mechanism that involves
disruption of microtubule polymerization and subse-
quent interference with the assembly of the NADPH
oxidase complex.73 Superoxide production by
neutrophils can be inhibited using low doses of1473
Clinical Therapeuticscolchicine and could be considered as a potential
therapy to reduce vascular dysfunction.
Results from a large-scale medical-records review
suggest that colchicine treatment may signiﬁcantly de-
crease cardiovascular risk.134 In that study, 1288 pa-
tients with gouty arthritis were identiﬁed by International
Classiﬁcation of Diseases, 9th Revision diagnostic code
from a larger sample of 40,107 patients enrolled in the
New York Harbor Healthcare System Veterans Affairs
network. Of the patients with gout, 576 had a history of
colchicine use and 712 did not. The prevalence of
myocardial infarction was signiﬁcantly lower among
colchicine users (P o 0.03), and there were numer-
ically but not signiﬁcantly lower mortality and CRP
levels among those with a history of colchicine use.134
The 2 groups had similar demographic characteristics,
comorbidities, cardiac risk factors, and concurrent
medication use (aside from colchicine); thus, these
factors were not held accountable for the difference in
outcomes between the 2 groups. Although the results
from that cross-sectional study suggested signiﬁcant
cardiovascular risk reduction with colchicine, pathways
underlying this effect have not been elucidated. The
investigators of the records review suggested that colchi-
cine may support plaque stability and/or reduce the
effects of plaque rupture and that these effects may have
been due to blockade macrophage activation, endothelial
activation, and/or neutrophil inﬂux and activation by
colchicine.134
A study by Nidorf et al135 evaluated the beneﬁt of
low-dose colchicine in the prevention of cardiovascular
events in patients with clinically stable coronary dis-
ease. In that prospective, randomized, observer-blinded
study in 532 patients with clinically stable coronary
disease, patients were randomized to receive colchicine
0.5 mg/d (n ¼ 282) or no colchicine (n ¼ 250) in
addition to standard therapies including aspirin and/or
statins. Patients were followed up for a median of 3
years. The primary end point was the composite
prevalence of acute coronary syndromes, out-of-
hospital cardiac arrest, and noncardioembolic ischemic
stroke. Of patients treated with colchicine, 5.3%
reported a primary end point incident compared with
16.0% of patients allocated to receive no colchicine (P
o 0.001). The effect was believed to have been the
result of the inhibition of neutrophil activation in
atherosclerotic plaques, thereby preventing the initia-
tion of inﬂammation, improving plaque stability and
reducing the risk for plaque enlargement and rupture.1474Additional well-controlled clinical trials are required
before colchicine can be recommended for the primary
or secondary prevention of cardiovascular disease.
CONCLUSIONS
Colchicine is a widely used and recommended ﬁrst-
line therapy for the treatment of acute gouty arthritis
ﬂares and ﬂare prophylaxis. Although colchicine has
many actions that predict efﬁcacy in protecting against
and treating gout ﬂares, the exact mechanisms of
action underlying its efﬁcacy have not been completely
elucidated and remain under active investigation.
Results obtained to date suggest that colchicine down-
regulates multiple pro-inﬂammatory pathways and
increases levels of antiinﬂammatory mediators. These
pleiotropic effects of colchicine may ultimately expand
the use of this agent to other therapeutic areas.
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